Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
ABSTRACT Anemia is the most common complication of end‐stage renal disease (ESRD). While erythropoiesis‐stimulating agents (ESA) have improved treatment outcomes, some patients exhibit intolerance or hyporesponsiveness. Roxadustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI), i...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2025-10-01
|
| Colección: | Clinical Case Reports |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1002/ccr3.70985 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|